EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview

Yufeng Du iD, Mohammad Arian Hassani iD, Chunhong Li, Zhijia Zhao iD, Yikun Liu, Chengtao Zhang iD, Jinsong Yan iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70450 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Yufeng Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospit…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Central Guidance on Local Science and Technology Development Fund of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Refractory/relapsed acute myeloid leukemia (R/R‐AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the primary treatment option in such patients. However, posttransplant relapse is still a challenge, with no established effective regimens. Case In this case report, we present the case of a 40‐year‐old male diagnosed with R/R‐AML who underwent salvage allo‐HSCT. Unfortunately, after 4 months of follow‐up, a relapse occurred. We modified the immunosuppressive therapy and administered donor lymphocyte infusion (DLI) and decitabine but failed to obtain complete remission (CR). Subsequently, a combination of venetoclax (Ven) and azacitidine (Aza), followed by the DLI regimen, was initiated. The patient achieved CR with no measurable residual disease.

Conclusion

Our data suggest that the administration of Ven in combination with Aza followed by the DLI regimen used for early post‐HSCT relapsed AML could serve as a valuable reference for treating similar patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansMaleAdultSalvage TherapyTransplantation, HomologousAzacitidineLymphocyte TransfusionRemission InductionTreatment Outcome

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationazacitidinedonor lymphocyte infusionrefractory/relapsedvenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAzacitidine

Autor:innen und Institutionen

  • Department of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.
  • Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Medical University, Dalian, China.
  • School of Public Health, Dalian Medical University, Dalian, China.
  • Department of Pediatrics, Pediatric Oncology and Hematology Center, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.

ORCID-Profile: Yufeng Du, Mohammad Arian Hassani, Zhijia Zhao, Chengtao Zhang, Jinsong Yan

Förderung

  • Central Guidance on Local Science and Technology Development Fund of Liaoning Province

Zitieren

APA

Du, Y., Hassani, M. A., Li, C., Zhao, Z., Liu, Y., Zhang, C., & Yan, J. (2026). Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview. Cancer Reports. https://doi.org/10.1002/cnr2.70450

Vancouver

Du Y, Hassani MA, Li C, Zhao Z, Liu Y, Zhang C, et al. Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview. Cancer Reports. 2026. doi:10.1002/cnr2.70450

BibTeX
@article{Du2026,
  author = {Du, Yufeng and Hassani, Mohammad Arian and Li, Chunhong and Zhao, Zhijia and Liu, Yikun and Zhang, Chengtao and Yan, Jinsong},
  title = {Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70450}
}
Kostenlos starten →